Back to companies

Axsome Therapeutics Inc: Overview

Axsome Therapeutics Inc (Axsome) is a biopharmaceutical company that develops and commercializes therapies for the treatment of central nervous system (CNS) disorders. The company’s pipeline product portfolio comprises AXS-05, for the treatment of resistant depression, smoking cessation and agitation in Alzheimer’s disease, AXS-07-migraine, AXS-12-narcolepsy, and AXS-14, for the treatment of fibromyalgia. Its other products include sunosi and auvelity. The company supplies its products through internal sales, distributors, and an internal marketing group in the US and outside the US. Axsome is headquartered in New York City, New York, the US.

Gain a 360-degree view of Axsome Therapeutics Inc and make more informed decisions for your business Gain a 360-degree view of Axsome Therapeutics Inc and make more informed decisions for your business Contact Us
Headquarters United States of America

Address One World Trade Center, 22nd Floor, New York, 10007


Telephone 1 212 3323241

No of Employees 383

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange AXSM (NASD)

Revenue (2023) $270.6M 440.8% (2023 vs 2022)

EPS XYZ

Net Income (2023) XYZ -27.8% (2023 vs 2022)

Market Cap* $3.6B

Net Profit Margin (2023) XYZ 76.4% (2023 vs 2022)

* As of and is in US$
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Contact Us

Axsome Therapeutics Inc premium industry data and analytics

70+

Catalyst Calendar

Proactively evaluate Axsome Therapeutics Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

50+

Clinical Trials

Determine Axsome Therapeutics Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

11+

Pipeline Drugs

Identify which of Axsome Therapeutics Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

6

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

5

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

2

Marketed Drugs

Understand Axsome Therapeutics Inc’s commercialized product portfolio to stay one step ahead of the market.

Products and Services

Products
Pipeline
AXS-14-Fibromyalgia
AXS-05-Alzheimer Disease
XYZ
XYZ
XYZ
Understand Axsome Therapeutics Inc portfolio and identify potential areas for collaboration Understand Axsome Therapeutics Inc portfolio and identify potential areas for collaboration Contact Us

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Plans/Strategy In June, the company announced its plans to sell its shares of its common stock in an underwritten public offering.
2023 Contracts/Agreements In February, the company entered into a license agreement with Pharmanovia to commercialize and further develop Sunosi.
2022 New Products/Services In November, the company announced that AXS-05, a novel, oral, investigational NMDA receptor antagonist.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Contact Us
Image for loader

Competitor Comparison

Key Parameters Axsome Therapeutics Inc Merck & Co Inc Pfizer Inc AbbVie Inc GSK plc
Headquarters United States of America United States of America United States of America United States of America United Kingdom
City New York Kenilworth New York North Chicago Brentford
State/Province New York New Jersey New York Illinois England
No. of Employees 383 69,000 88,000 50,000 69,400
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Contact Us
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Contact Us
Executives
Name Position Board Since Age
Herriot Tabuteau Chief Executive Officer; Chairman Executive Board 2012 54
Nick Pizzie Chief Financial Officer Senior Management 2018 48
Mark Jacobson Chief Operating Officer Senior Management 2020 39
Hunter Murdock Executive Vice President - Legal and Compliance Senior Management 2021 -
Lori Englebert Senior Vice President - Commercial and Business Development Senior Management 2020 45
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Axsome Therapeutics Inc key executives to enhance your sales strategy Gain insight into Axsome Therapeutics Inc key executives to enhance your sales strategy Contact Us
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward